The technique of gene silencing using antisense oligonucleotides is of high interest to investigators involved in drug development. In theory, this technology provides a means of specifically targeting the expression of a single gene product. The ever-expanding field of antisense technology now covers a wide range of substances including oligonucleotides, peptide nucleic acids as well as small interfering ribonucleic acids or RNA interference. Antisense technology has developed over the past decade to the stage where there are now several clinical trials evaluating the safety as well as efficacy of these agents in clinical oncology. With rapid developments in synthesis of the oligonucleotides, modifications that make the oligonucleotides more stable, and identification of more tumor-specific targets, it is likely that antisense oligonucleotides will become useful in cancer therapy. These drugs appear to be well tolerated and may be combined with conventional chemotherapeutic agents for better antitumor effects.
American Journal of Cancer – Springer Journals
Published: Aug 10, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.